display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic glioblastoma (mGB) - 1st line (L1)
metastatic glioblastoma (mGB) - 1st line (L1)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone Checkmate 143

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons